Physician profile
Peter Georges
NPI 1861699944
$91,421.48
in general payments reported to CMS, 2019-2025
40 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,665 · 2020: $570 · 2021: $7,417 · 2022: $9,851 · 2023: $12K · 2024: $42K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $4,562 · Food and Beverage: $2,637 · Honoraria: $1,500 · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,839.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,936.00 |
| Travel and Lodging | $4,562.11 |
| Food and Beverage | $2,636.93 |
| Honoraria | $1,500.00 |
| Education | $443.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30,515.44 | 2021-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $12,389.92 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pharmacosmos Therapeutics INC. | $7,317.25 | 2022-2023 | Monoferric |
| Jazz Pharmaceuticals INC. | $7,269.36 | 2023-2024 | Zepzelca |
| Astellas Pharma US INC | $7,254.55 | 2019-2025 | Xospata, Padcev, Xtandi |
| Incyte Corporation | $7,094.85 | 2019-2025 | |
| Gilead Sciences, INC. | $4,332.05 | 2021-2024 | Trodelvy |
| Abbvie INC. | $3,944.97 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $2,440.00 | 2024-2025 | Darzalex, Talvey |
| Pfizer INC. | $2,195.42 | 2019-2025 | |
| Tg Therapeutics, INC. | $1,665.00 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Puma Biotechnology, INC. | $1,299.79 | 2019 | |
| Lilly USA, LLC | $419.52 | 2019-2025 | Verzenio |
| Janssen Biotech, INC. | $268.07 | 2019-2024 | Erleada |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Georges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.